We recently updated our Privacy Notice and Terms of Use.
Med-IQ
IBS-D Treatment: Incorporating Effective Strategies in a New Era
E-publication E-publication

IBS-D Treatment: Incorporating Effective Strategies in a New Era


Presented by the AGA Institute and Med-IQ.

AGA InstituteMed-IQ

Time to Complete:
30 minutes
Released:
8/16/16
Expires:
8/15/17

Maximum Credits:

0.5

E-publication E-publication
Time to Complete:
30 minutes

Released:
8/16/16

Expires:
8/15/17

Maximum Credits:
0.5
E-publication E-publication

Time to Complete:
30 minutes
Released:
8/16/16
Expires:
8/15/17


Maximum Credits:
0.5


Overview: This CME-certified publication reviews treatment options for patients with irritable bowel syndrome with diarrhea (IBS-D) and focuses on the practical aspects of incorporating newly approved agents into clinical practice. Key topics to be discussed include the diagnosis of IBS, the safety and efficacy of recently approved pharmacologic agents, and practical considerations for optimizing treatment. This publication also incorporates faculty insights from a symposium that took place at Digestive Disease Week 2016 and includes a case vignette to highlight the real-world applications of using recently approved pharmacologic agents in everyday practice.

CME Information:

Faculty
William D. Chey, MD, AGAF, FACG, FACP, RFF
Timothy T. Nostrant Professor of Gastroenterology & Nutrition Sciences
Director, GI Physiology Laboratory
Medical Director, Michigan Bowel Control Program
Director, Digestive Disease Nutrition & Lifestyle Program
Division of Gastroenterology
University of Michigan Health System
Ann Arbor, MI

Anthony J. Lembo, MD, AGAF
Associate Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, MA

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Maura H. Davis
Director of Education
American Gastroenterological Association
Bethesda, MD

Sandra Megally
Senior Manager, Education
American Gastroenterological Association
Bethesda, MD

Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Med-IQ
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Identify patients with IBS-D who are appropriate candidates for pharmacotherapy
  • Develop individualized treatment plans for patients with IBS-D by applying new clinical data
Target Audience
This activity is intended for United States (US)-based gastroenterologists.

Series Overview/Statement of Need
Approximately 10% to 15% of adults in the US suffer from irritable bowel syndrome (IBS), 30% of whom also experience diarrhea (IBS-D). The challenges associated with IBS are substantial, including reduced productivity and avoidance of places that do not have bathrooms nearby. In 2015, the US Food and Drug Administration approved 2 new treatments for the management of IBS-D. However, guidelines have not yet incorporated specific recommendations for using these new agents. This publication focuses on diagnosing patients with IBS and provides clinical evidence and expert insight to discuss the appropriate use of new agents in clinical practice.

Sponsorship Statement
Presented by the AGA Institute and Med-IQ.

Accreditation/Designation Statements
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Original Release Date: August 16, 2016
Expiration Date: August 15, 2017
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

William D. Chey, MD, AGAF, FACG, FACP, RFF
Consulting fees/advisory boards: Actavis, Ardelyx, AstraZeneca, IM Health, Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus Laboratories Inc., QOL Medical, LLC, SK Biopharmaceuticals Co., Ltd., Takeda Pharmaceuticals North America, Inc., Sucampo Pharmaceuticals, Inc.
Contracted research: IM Health, Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus Laboratories Inc., Vibrant Pharma Inc.

Anthony J. Lembo, MD, AGAF
Consulting fees/advisory boards: Alkermes, Allergan, Inc., Ironwood Pharmaceuticals, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc.

The peer reviewers and other activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later

Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/

Google Chrome - latest version
Download: http://www.google.com/chrome

Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/

For technical support, go to https://www.med-iq.com/index.cfm?fuseaction=content.support.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.Med-IQ.com/privacy-statement/.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.

Copyright
© 2016 the AGA Institute and Med-IQ®. All rights reserved.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.